You are about to leave jnjmedicaldevices.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
ORTHOVISC® High Molecular Weight Hyaluronan
ORTHOVISC® High Molecular Weight Hyaluronan is a FDA approved treatment made from ultra-pure hyaluronan, a naturally occurring lubricant found in healthy knee joints. ORTHOVISC® Hyaluronan is a non-avian sourced hyaluronic acid injection therapy which has up to six months of clinically proven efficacy with 3 or 4 injections.1
As OA of the knee progresses, prescription medications such as NSAIDs, COX-2 Inhibitors and intraarticular corticosteroid injections may be appropriate next course of therapy choices. Due to contraindications, co-morbidities or adverse events, COX-2 Inhibitors and/or NSAIDs may or may not be an appropriate choice.
These treatments may have provided relief to date but may no longer seem effective due to the disease state progression. A next-step consideration in the Continuum of Care for Knee Osteoarthritis is Hyaluronic Acid Injections, such as ORTHOVISC® Hyaluronan.
Features & Benefits
Efficacy
ORTHOVISC® has proven efficacy across 26 weeks of randomized controlled trials.1,2 ORTHOVISC® provided significant improvement in WOMAC pain score versus saline with up to 6 months of symptom relief with 3 or 4 injections.
Safety
Because ORTHOVISC® closely resembles the properties of healthy synovial fluid, the expectation is that adverse events (AE) should be minimal. Clinical studies have demonstrated that the safety of ORTHOVISC® is shown to be similar to saline injection.1
Purity
ORTHOVISC® contains no additives and is derived from bacterial cells, enabling it to be prescribed to patients with known avian allergies. Repeat courses may be safely administered.1
References
1 ORTHOVISC® (high molecular weight hyaluronan) Full Prescribing Information. DePuy Mitek: Raynham, MA. Revised June 2005.
2 Brandt KD, Block JA, Michalski JP, et al. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. Clin Orthop Relat Res. 2001;385:130-143.
3 Synvisc® (hylan G-F 20) manufacturer’s full prescribing information.
4 Synvisc-One® (hylan G-F 20) manufacturer’s full prescribing information.
5 Gel-One® (cross-linked hyaluronate) manufacturer’s full prescribing information.
6 Hyalgan® (sodium hyaluronate) manufacturer’s full prescribing information.
7 Supartz® (sodium hyalronate) manufacturer’s full prescribing information
8 Euflexxa® (1% sodium hyaluronate) manufacturer’s full prescribing information.
Indication Statement
Indications
ORTHOVISC® Hyaluronan is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics, e.g. acetaminophen. ORTHOVISC® Hyaluronan may enhance the viscoelastic properties of synovial fluid to relieve pain and increase mobility.
ORTHOVISC® is manufactured by and is a registered trademark of Anika Therapeutics, Inc.
All medical devices have associated risks. Please refer to the package insert and other labeling for a complete list of indications, contraindications, precautions and warnings. For further information on DePuy Synthes Products, please contact your local DePuy Synthes Representative.
094211-180628
© DePuy Synthes 2020. All Rights Reserved. This site is published by the DePuy Synthes Companies, which are solely responsible for its content. This site is governed solely by applicable U.S. laws and governmental regulations. This site is for visitors from the United States. The third party trademarks used herein are the trademarks of their respective owners.